Eli Lilly’s ongoing Platform Technology Evaluation Agreement with Peptron for SmartDepot, a sustained-release microsphere formulation using ultrasonic spray drying for long-acting peptide delivery, remains in the joint research phase with no commercial licensing or technology transfer announced. The non-exclusive deal, extended through October 7, 2026, allows Lilly to test the platform on its peptide candidates including GLP-1 assets, yet Lilly’s separate exclusive licensing of Camurus’ competing FluidCrystal technology for incretin therapies and its pivot toward oral obesity candidates have reduced near-term urgency. Recent reporting confirms continued technical work, including expanded CNS applications, but highlights the evaluation’s optional nature and potential for termination with notice. With the deadline now weeks away and no binding deal disclosed, trader consensus heavily favors “No” at 87.5% implied probability.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing Platform Technology Evaluation Agreement with Peptron for SmartDepot, a sustained-release microsphere formulation using ultrasonic spray drying for long-acting peptide delivery, remains in the joint research phase with no commercial licensing or technology transfer announced. The non-exclusive deal, extended through October 7, 2026, allows Lilly to test the platform on its peptide candidates including GLP-1 assets, yet Lilly’s separate exclusive licensing of Camurus’ competing FluidCrystal technology for incretin therapies and its pivot toward oral obesity candidates have reduced near-term urgency. Recent reporting confirms continued technical work, including expanded CNS applications, but highlights the evaluation’s optional nature and potential for termination with notice. With the deadline now weeks away and no binding deal disclosed, trader consensus heavily favors “No” at 87.5% implied probability.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing Platform Technology Evaluation Agreement with Peptron for SmartDepot, a sustained-release microsphere formulation using ultrasonic spray drying for long-acting peptide delivery, remains in the joint research phase with no commercial licensing or technology transfer announced. The non-exclusive deal, extended through October 7, 2026, allows Lilly to test the platform on its peptide candidates including GLP-1 assets, yet Lilly’s separate exclusive licensing of Camurus’ competing FluidCrystal technology for incretin therapies and its pivot toward oral obesity candidates have reduced near-term urgency. Recent reporting confirms continued technical work, including expanded CNS applications, but highlights the evaluation’s optional nature and potential for termination with notice. With the deadline now weeks away and no binding deal disclosed, trader consensus heavily favors “No” at 87.5% implied probability.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing Platform Technology Evaluation Agreement with Peptron for SmartDepot, a sustained-release microsphere formulation using ultrasonic spray drying for long-acting peptide delivery, remains in the joint research phase with no commercial licensing or technology transfer announced. The non-exclusive deal, extended through October 7, 2026, allows Lilly to test the platform on its peptide candidates including GLP-1 assets, yet Lilly’s separate exclusive licensing of Camurus’ competing FluidCrystal technology for incretin therapies and its pivot toward oral obesity candidates have reduced near-term urgency. Recent reporting confirms continued technical work, including expanded CNS applications, but highlights the evaluation’s optional nature and potential for termination with notice. With the deadline now weeks away and no binding deal disclosed, trader consensus heavily favors “No” at 87.5% implied probability.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions